FDA panel’s negative vote clouds AstraZeneca’s bid for camizestrant in advanced breast cancer

AstraZeneca ( (GB:AZN) ) has shared an announcement.

AstraZeneca has suffered a setback in the U.S. after the FDA’s Oncologic Drugs Advisory Committee voted 6–3 against supporting the benefit‑risk profile of its investigational breast cancer drug camizestrant when combined with a CDK4/6 inhibitor for first‑line treatment of HR‑positive, HER2‑negative advanced breast cancer with emergent ESR1 mutations. While the FDA is not bound by the panel’s recommendation and continues to review the application, the outcome introduces regulatory uncertainty around a potential new revenue stream and may slow AstraZeneca’s push to expand its leadership in endocrine‑resistant breast cancer.

The decision contrasts with strong Phase III SERENA‑6 data, which showed a 56% reduction in risk of disease progression or death and extended median progression‑free survival to 16.0 months versus 9.2 months for standard aromatase inhibitor combinations, with no new safety signals. AstraZeneca emphasised the innovative ctDNA‑guided trial design, clinically meaningful improvements in progression and quality‑of‑life measures, and ongoing global filings in the EU, Japan and other markets, underscoring its intent to continue developing camizestrant as a cornerstone therapy for HR‑positive, HER2‑negative breast cancer despite the mixed U.S. advisory outcome.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £160.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Spark’s Take on AZN Stock

According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.

The score is driven primarily by strong fundamentals (growth and profitability) and a constructive earnings outlook with pipeline and guidance support. It is held back by weak technical momentum and a valuation that looks elevated relative to the modest dividend yield, alongside near-term risks (notably Farxiga LOE and China pricing pressure).

To see Spark’s full report on AZN stock, click here.

More about AstraZeneca

AstraZeneca is a global biopharmaceutical company focused on the discovery, development and commercialisation of prescription medicines, with a strong presence in oncology. The group’s oncology portfolio targets major tumour types including breast, lung, ovarian and blood cancers, positioning it as a key player in targeted and precision cancer therapies.

Average Trading Volume: 2,668,518

Technical Sentiment Signal: Buy

Current Market Cap: £212.3B

See more data about AZN stock on TipRanks’ Stock Analysis page.